Closing arguments began Monday in a civil trial over whether the Los Angeles Angels should be held responsible for the fatal ...

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with ...

EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Gearing Up for Phase 2 Vitiligo Trial in Mid-2026 Edesa Biotech, Inc.

After Bengaluru, Mangaluru has emerged as a major centre in the expanding and dangerous narcotics network in the state.

Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease ...

AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's ...

The company intends to file a U.S. application in the first half of 2026 following positive study results in a condition ...

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.

Argenx stock toppled Monday after the biotech scrapped plans to develop its blockbuster drug, Vyvgart, for thyroid eye ...

Scientists have been obsessed with finding the origin of Alzheimer's disease for decades. We know that it occurs because ...

(11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall ...